August 13, 2025 — Adaptimmune Therapeutics plc (NASDAQ: ADAP) reported its financial results and a business update for the second quarter ending June 30, 2025. Q2 Tecelra sales reached $11.1 million with 16 patients invoiced, marking a growth of over 150% compared to Q1 2025.
The company entered a definitive agreement to sell TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront, with potential future milestone payments up to $30 million. Following the transaction, Adaptimmune repaid its debt and is restructuring to maximize value from remaining assets, including PRAME and CD70 directed T-cell therapies.
Adaptimmune’s CEO, Adrian Rawcliffe, noted the accelerated launch of TECELRA in Q2 and the near completion of the ATC network, with 30 sites now accepting referrals. Rawcliffe stated that the transaction with US WorldMeds will ensure continued patient access to TECELRA and place lete-cel in capable hands for its planned 2026 launch. The deal follows an extensive review of strategic alternatives and is considered the best path forward for Adaptimmune and its stakeholders. After closing the transaction on July 31, the company repaid its debt facility with Hercules Capital and is restructuring to support the assets transferred to US WorldMeds, maximizing value from remaining assets targeting PRAME and CD70.
As of June 30, 2025, Adaptimmune had cash and cash equivalents of $26.1 million, compared to $91.1 million as of December 31, 2024. Revenue for the three and six months ending June 30, 2025, was $13.7 million and $21.0 million, respectively, compared to $128.2 million and $133.9 million for the same periods in 2024.
R&D expenses for the three and six months ending June 30, 2025, were $23.0 million and $51.8 million, respectively, compared to $40.4 million and $75.7 million for the same periods in 2024. SG&A expenses for the three and six months ending June 30, 2025, were $18.5 million and $41.8 million, respectively, compared to $19.1 million and $38.8 million for the equivalent periods in 2024.
Net loss attributable to holders of the Company’s ordinary shareholders for the three and six months ended June 30, 2025, were $30.3 million and $77.9 million respectively ($(0.02) and $(0.05) per ordinary share), compared to profits of $69.5 million and $21.0 million ($0.05 and $0.01 per ordinary share), for the equivalent periods in 2024.
Contact:
Adrian Rawcliffe, Chief Executive Officer
Adrian.Rawcliffe@adaptimmune.com
Source: Adaptimmune
